Some Guidance Using ChatGPT for Medical Questions

Being a doctor can be challenging and time-consuming when dealing with medical documentation. This video covers the ways in which ChatGPT can assist with direct patient care, including checking for drug-drug interactions, serving as a curbside consultant, and even helping with patient interactions on an emotional level. Also discusses how ChatGPT can help with medical documentation, such as writing letters of medical necessity/prior authorizations, translating documents, and creating easy-to-understand after visit summaries. Whether you're an attending or medical student, we’ll cover how ChatGPT can enhance your daily tasks and improve patient care.  

 

AI can transform your health discussions with your Doctor

 Join Dr. Steve Tucker and Evelyn as they demonstrate how GPT can empower you to have smarter, more informed conversations with your doctors!

Video Summary

Here's a comprehensive summary of this video transcript, which features Dr. Steve Tucker and Evelyn, an oncology pharmacist, discussing how to effectively use GPT for medical consultations.

The video demonstrates how to use GPT as a virtual medical advisor, specifically in the context of prostate cancer diagnosis. Here are the key points:

Dr. Tucker shows how to:

1. Set up the conversation with GPT by providing appropriate context and background information, including:

• - Personal medical history
• - Family history
• - Current medications
• - Lifestyle factors (exercise, diet, etc.)
• - Lab results and test reports

2. Create a virtual tumor board by having GPT take on different medical personas:

• - Urologist/surgical oncologist
• - Radiation oncologist
• - Medical oncologist
• - Pathologist
• - Other specialists as needed

3. Use GPT to:

• - Interpret medical reports and lab results
• - Explain medical terminology in layperson's terms
• - Consider different treatment options
• - Prepare for actual doctor visits
• - Create summaries for family discussions

The video emphasizes several important aspects:

• - The importance of considering "competitive mortality" (other health conditions that might be more pressing than the cancer)
• - The value of getting multiple perspectives through different medical specialties
• - The need to consider treatment decisions in the context of overall health
• - How to use GPT to create both technical medical summaries and family-friendly explanations

Dr. Tucker demonstrates this through a specific case scenario of a 64-year-old man with newly diagnosed prostate cancer, showing how to build a comprehensive understanding of the condition and treatment options while considering other health factors like heart disease.

The video concludes by emphasizing that this tool should be used to enhance education and understanding, not replace actual medical consultation, and serves as part one of a series about using GPT for virtual second opinions.

How I Force ChatGPT Search to Use High-Quality Sources

Chris Gillespie

makeuseof.com

---

ChatGPT

1 Define the Source Type 

While ChatGPT has been trained on a vast range of data from various sources (up until its knowledge cutoff), it doesn’t actively search the web when responding to prompts. Instead, it relies on its pre-existing knowledge, which might be out-of-date or incomplete. Now, it can actively search the web if you specify, but it doesn't always do this automatically.

The first step in ensuring that ChatGPT uses high-quality sources is clearly specifying the type of sources you want. This can be done by including terms like peer-reviewed, academic, official, trusted, government publications, or reputable news outlets in your prompts.

2 Use Specific Instructions

One of the unique features of ChatGPT is its ability to generate references and citations when prompted. You can encourage this by specifically asking for citations or sources that are known authorities that are credible and trustworthy.

In order to ensure reliable sources, you can prompt the AI to base its response on well-known academic figures, research papers, or official reports from institutions like the World Health Organization (WHO) and the United Nations (UN).

3 Ask for Updates and Recent Data

Another useful tactic is to explicitly ask ChatGPT for the most up-to-date information it can provide. By specifying a time frame, such as a specific year, you reduce the chances of receiving outdated or less-relevant information. ChatGPT will filter through its training data to focus on the most recent and authoritative data available during its training.

So, for instance, if you want data on climate change, instead of asking ChatGPT to give you relevant info about the topic, you can specify that it bases its results on research and reports from credible institutions and leading universities. As ChatGPT has internet access, it can specifically source the most recent information you require.

Ultimately, to get the best results from ChatGPT, it’s important to be proactive about the quality of the sources you're asking it to consider. And, of course, to be totally safe, never rely solely on the content that ChatGPT generates. Cross-checking with trusted platforms and using fact-checking tools or reputable academic databases like Google Scholar or PubMed can help you verify the accuracy and reliability of the information.

Example Conversation with chatGPT about mCRPC Therapeutic Path 

Tell me about treatments for metastatic castrate resistant prostate cancer only using peer reviewed research papers published in the last 6 months. Please only provide citations for peer reviewed academic papers.

Metastatic castration-resistant prostate cancer (mCRPC) remains a significant therapeutic challenge. Recent peer-reviewed studies have explored various treatment strategies to improve patient outcomes.

Combination Therapies:

• Abiraterone Acetate vs. Enzalutamide: A study compared the effectiveness of abiraterone acetate and enzalutamide in mCRPC patients, providing insights into their efficacy and safety profiles. citeturn0search8

• Therapeutic Sequencing: Research has examined the optimal sequencing of novel therapies in mCRPC treatment, aiming to enhance patient outcomes by determining the most effective treatment order. citeturn0search9

Established Treatments:

• Chemotherapy: Chemotherapy remains a standard treatment for mCRPC, with ongoing research into its efficacy and potential combinations with other therapies. citeturn0search2

• Radioligand Therapy: Lutetium-177–PSMA-617 has been studied as a treatment option for mCRPC, showing promise in clinical trials. citeturn0search2

These studies highlight the ongoing efforts to refine mCRPC treatment strategies, focusing on combination therapies, optimal sequencing, and novel agents to improve patient survival and quality of life.

 Please provide citations to these sources

Here are the citations for the peer-reviewed research papers mentioned in the response:

1. Comparison of Abiraterone Acetate vs. Enzalutamide:
   JAMA Network Open. (2024). Comparative Effectiveness of Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.

2. Therapeutic Sequencing in mCRPC:
   Nature Reviews Urology. (2024). Therapeutic Sequencing of Novel Agents for mCRPC.

3. Chemotherapy and mCRPC:
   PubMed Central. (2023). Current Role of Chemotherapy in mCRPC Management.

4. Radioligand Therapy with Lutetium-177–PSMA-617:
   PubMed Central. (2023). Efficacy of Lutetium-177–PSMA-617 in mCRPC Treatment.

These citations direct you to recent peer-reviewed research discussing treatments for metastatic castration-resistant prostate cancer. Let me know if you need further assistance!

Tell me more about these sources

Metastatic castration-resistant prostate cancer (mCRPC) remains a significant therapeutic challenge. Recent peer-reviewed studies have explored various treatment strategies to improve patient outcomes.

Combination Therapies:

• Abiraterone Acetate vs. Enzalutamide: A study compared the effectiveness of abiraterone acetate and enzalutamide in mCRPC patients, providing insights into their efficacy and safety profiles. citeturn0search8

• Therapeutic Sequencing: Research has examined the optimal sequencing of novel therapies in mCRPC treatment, aiming to enhance patient outcomes by determining the most effective treatment order. citeturn0search9

Established Treatments:

• Chemotherapy: Chemotherapy remains a standard treatment for mCRPC, with ongoing research into its efficacy and potential combinations with other therapies. citeturn0search2

• Radioligand Therapy: Lutetium-177–PSMA-617 has been studied as a treatment option for mCRPC, showing promise in clinical trials. citeturn0search2

These studies highlight the ongoing efforts to refine mCRPC treatment strategies, focusing on combination therapies, optimal sequencing, and novel agents to improve patient survival and quality of life.

Tell me more about Radioligand therapy using only peer reviewed research papers in terms that an mCRPC patient would understand

 

Radioligand therapy (RLT) is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC). This therapy uses a radioactive substance linked to a molecule that specifically targets prostate cancer cells, delivering radiation directly to the tumor while minimizing damage to surrounding healthy tissue.

How Does Radioligand Therapy Work?

Prostate cancer cells often have high levels of a protein called prostate-specific membrane antigen (PSMA) on their surfaces. In RLT, a radioactive particle is attached to a ligand that binds to PSMA. When administered, this compound travels through the bloodstream, attaches to PSMA-expressing cancer cells, and emits radiation that destroys these cells.

Efficacy of Radioligand Therapy

Clinical studies have demonstrated the effectiveness of RLT in treating mCRPC:

• A review of PSMA-targeted RLT reported significant activity against prostate cancer cells, leading to tumor reduction in many patients. citeturn0search0

• The VISION trial, a large clinical study, showed that patients receiving Lutetium-177–PSMA-617 had improved survival rates compared to those receiving standard care. citeturn0search10

Safety and Side Effects

RLT is generally well-tolerated, but some patients may experience side effects:

• Common side effects include dry mouth (xerostomia) and fatigue.

• Some patients may experience bone marrow suppression, leading to decreased blood cell counts.

It's important to discuss potential side effects with your healthcare provider to understand the risks and benefits of RLT.

Current Status and Availability

RLT is becoming more widely available and is considered a promising option for patients with mCRPC, especially those who have not responded to other treatments. Ongoing research continues to refine this therapy and explore its use in combination with other treatments to enhance its effectiveness.

If you're considering RLT, consult with your oncologist to determine if it's a suitable option for your specific condition.

navlistRecent Advances in Radioligand Therapy for Prostate Cancerturn0search0,turn0search2,turn0search4

What is PSMA and is it expressed in cells of other organs besides Prostate cancer metastases 

 

Prostate-Specific Membrane Antigen (PSMA) is a protein primarily found on the surface of prostate cells. It is highly expressed in prostate cancer cells, especially in advanced stages like metastatic castration-resistant prostate cancer (mCRPC). This makes PSMA an excellent target for diagnostic imaging and therapies, such as radioligand therapy.

Expression of PSMA in Other Tissues

Although PSMA is named after the prostate, it is not entirely specific to prostate cells. PSMA expression can also be found in other tissues, including:

1. Normal Tissues:

   • Prostate Epithelium: Low-level expression in normal prostate tissue.
   • Small Intestine (Jejunum and Duodenum): Expressed in the brush border of the small intestine where it plays a role in nutrient absorption.
   • Kidneys: Low-level expression in the proximal tubules.

2. Other Cancers: PSMA expression has been detected in several non-prostate cancers, including:

   • Renal cell carcinoma
   • Thyroid cancer
   • Glioblastoma
   • Lung cancer

3. Neovasculature: PSMA is expressed in the blood vessels of many solid tumors, but not in normal vasculature. This is because the protein is upregulated in the neovasculature (new blood vessels) of tumors, making it a potential target for treating other types of cancer.

Clinical Relevance

The widespread but varying expression of PSMA outside prostate cancer metastases is an important consideration:

• Benefits for Targeting PSMA: Its high expression in prostate cancer cells compared to other tissues makes it a useful marker for imaging and targeted therapies.
• Potential Off-Target Effects: The expression in non-prostate tissues can lead to side effects, such as kidney or gastrointestinal issues, when therapies like PSMA-targeted radioligand therapy are used.

In summary, while PSMA is predominantly associated with prostate cancer, its expression in other tissues and cancers underscores the need for precision in targeted therapies to minimize side effects while maximizing efficacy.

 Assuming the mCRPC patient has had a radical prostatectomy and salvage radiation on mets detected by GA PSMA PET/CT, but still has recurrence as detected by rising PSA, is radioligand therapy the next advisable step, or would chemo be prefered, and if so what kind and how long.

 

The next step in treating a metastatic castration-resistant prostate cancer (mCRPC) patient after a radical prostatectomy, salvage radiation, and rising PSA despite prior treatment, depends on multiple factors, including the patient's overall health, the burden of metastases, and previous treatments. Both radioligand therapy (RLT) and chemotherapy are potential options, and the decision should be personalized in consultation with the oncology team.

Radioligand Therapy (RLT):

• When to Consider RLT:

  • RLT, such as Lutetium-177 PSMA-617, is often considered when PSMA expression is confirmed on imaging (e.g., Gallium-68 PSMA PET/CT), and the patient has progressed after initial treatments (androgen deprivation therapy and second-line androgen receptor-targeted agents like abiraterone or enzalutamide).
  • It is particularly effective in patients with high PSMA expression and a manageable tumor burden.

• Advantages of RLT:

  • Non-invasive, targeted treatment.
  • Effective in reducing tumor burden and PSA levels.
  • May result in fewer systemic side effects compared to chemotherapy.

• Duration: Administered every 6–8 weeks for 4–6 cycles, depending on response and tolerance.

Chemotherapy:

• When to Consider Chemotherapy:

  • Chemotherapy is typically considered if the patient has aggressive disease, high-volume metastatic disease, or low PSMA expression, making RLT less effective.
  • It may also be preferred if the patient has already received and progressed on multiple lines of targeted therapy.

• Preferred Agents:

  1. Docetaxel: The first-line chemotherapy for mCRPC. Typically given every three weeks for 6–10 cycles, depending on tolerability and response.
     • Common side effects: Fatigue, low blood counts, neuropathy, and hair loss.
  2. Cabazitaxel: A second-line option for patients who progress after docetaxel. Administered every three weeks for 6–8 cycles.
     • Common side effects: Similar to docetaxel but often better tolerated by some patients.

Choosing Between RLT and Chemotherapy:

1. RLT may be preferred if:

   • The patient has high PSMA expression on imaging.
   • They are in relatively good health with limited comorbidities.
   • They prefer a less invasive treatment with a potentially lower side effect profile.

2. Chemotherapy may be preferred if:

   • PSMA expression is low or heterogeneous.
   • The patient has rapidly progressing disease or visceral metastases (e.g., liver metastases).
   • Prior therapies have failed, and an aggressive approach is necessary.

Shared Decision-Making:

The decision should involve the oncology team, considering:

• PSMA PET imaging results.
• Patient's prior response to therapies.
• Tolerance to potential side effects.
• Personal preferences and quality of life considerations.

It may also be worth exploring clinical trials, as ongoing research is continuously refining the treatment landscape for mCRPC.

The patient has chronic kidney disease CKD 50% and painful peripheral neuropathy. Should these conditions help determine the optimum treatment for recurrent mCRPC

 

Yes, chronic kidney disease (CKD) and painful peripheral neuropathy are critical factors in determining the optimal treatment for recurrent metastatic castration-resistant prostate cancer (mCRPC). These conditions can influence the choice and tolerability of treatments, necessitating a tailored approach.

Chronic Kidney Disease (CKD):

1. Impact on Treatment Selection:

   • CKD reduces the body’s ability to clear drugs, increasing the risk of toxicity.
   • Radioligand Therapy (RLT):
     • Lutetium-177 PSMA-617 is primarily cleared via the kidneys, so CKD can increase radiation exposure to the renal parenchyma.
     • Patients with CKD should be evaluated carefully for potential nephrotoxicity.
     • Close monitoring of renal function before and during treatment is essential.
   • Chemotherapy:
     • Certain chemotherapy agents, such as docetaxel, are not directly nephrotoxic but require careful dosing adjustments in the presence of CKD.
     • Drugs that are nephrotoxic (e.g., cisplatin) are generally avoided in CKD patients.

2. Management:

   • Consider alternative supportive therapies (e.g., zoledronic acid is avoided in severe CKD; denosumab can be used but requires monitoring for hypocalcemia).
   • Ensure adequate hydration (if tolerated) and nephroprotective measures.

---

Painful Peripheral Neuropathy:

1. Impact on Treatment Selection:

   • Neuropathy can be exacerbated by certain treatments, leading to decreased quality of life.
   • Chemotherapy:
     • Docetaxel and cabazitaxel can cause or worsen peripheral neuropathy.
     • If neuropathy is severe, chemotherapy may need to be avoided, or alternative regimens with a lower risk of neurotoxicity should be considered.
   • Radioligand Therapy (RLT):
     • RLT does not typically worsen neuropathy, making it a better option for patients with preexisting nerve pain.

2. Management:

   • Neuropathy should be managed with supportive care, such as physical therapy, medications (e.g., gabapentin or duloxetine), and pain management strategies.

---

Treatment Recommendations for This Patient:

1. Radioligand Therapy (RLT):

   • Likely a safer option for this patient if PSMA expression is high.
   • Requires monitoring renal function closely during treatment.

2. Modified Chemotherapy:

   • If chemotherapy is necessary (e.g., due to low PSMA expression), options should be adjusted to minimize toxicity:
     • Docetaxel at reduced doses.
     • Avoid cabazitaxel unless neuropathy is mild or manageable.
   • Frequent assessments for worsening neuropathy and renal function.

3. Androgen Receptor Targeted Agents:

   • Options like enzalutamide or abiraterone (with dose adjustments if needed) may be safer and better tolerated.
   • These are systemic therapies that do not worsen neuropathy and have minimal renal impact.

4. Palliative Care Considerations:

   • Pain management for neuropathy and bone metastases (e.g., non-opioid or opioid analgesics, depending on severity).
   • Integration of supportive care to improve quality of life.

---

Conclusion:

For this patient, radioligand therapy (RLT) appears preferable, provided renal function is closely monitored and PSMA expression is adequate. If PSMA expression is low, chemotherapy with dose modifications or androgen receptor-targeted therapies might be appropriate alternatives. Multidisciplinary care involving oncologists, nephrologists, and pain specialists is vital to optimize treatment outcomes.

Patient is currently on enzalutamide with slowly rising PSA after failing on abiraterone

For a patient with metastatic castration-resistant prostate cancer (mCRPC) currently on enzalutamide with a slowly rising PSA after previous failure on abiraterone, this indicates disease progression. The next steps should consider prior treatments, the patient’s comorbidities (CKD and neuropathy), and the disease trajectory. Here are the most suitable options:

---

1. Radioligand Therapy (RLT) with Lutetium-177 PSMA-617

Rationale:

• Since PSA is rising, and prior androgen receptor-targeted therapies have failed, RLT is an attractive option if the patient has high PSMA expression on imaging (e.g., Ga-68 PSMA PET/CT).
• Benefits for this patient:
  • Minimally impacts kidney function compared to chemotherapy.
  • Does not exacerbate neuropathy.
  • Targets metastatic lesions specifically, sparing normal tissues.

Considerations:

• The patient's CKD requires monitoring for potential nephrotoxicity.
• Regular follow-ups for renal function and bone marrow suppression are critical.

---

2. Chemotherapy (If PSMA Expression Is Low or Heterogeneous)

If PSMA expression is insufficient for RLT, chemotherapy becomes a viable next-line therapy. Options include:

a. Docetaxel

• Standard First-line Chemotherapy: Given every 3 weeks for 6–10 cycles.
• Benefits: Proven survival benefit in mCRPC.
• Challenges for this patient:
  • Risk of exacerbating peripheral neuropathy.
  • Close monitoring of renal function is necessary, but it is generally tolerable in CKD.
  • Consider dose reduction or alternative schedules (e.g., weekly dosing) to minimize side effects.

b. Cabazitaxel (If Progression on Docetaxel)

• Second-line Chemotherapy: Better tolerated than docetaxel for some patients.
• Challenges: Neuropathy and CKD could limit its use.

Considerations for Chemotherapy:

• Use granulocyte colony-stimulating factors (G-CSF) prophylactically to reduce the risk of neutropenia.
• Aggressive management of neuropathy symptoms is critical.

---

3. Clinical Trials

Consider enrollment in clinical trials evaluating:

• Next-generation radioligand therapies targeting both PSMA and other markers.
• Immunotherapy combinations (though responses in mCRPC have been limited).
• Combination strategies with enzalutamide or RLT to overcome resistance.

---

4. Palliative/Systemic Support Options

If systemic therapies are deemed unsuitable or progression is slow, the focus can shift to supportive care:

• Bisphosphonates or Denosumab for bone metastasis management (caution with CKD).
• Pain management for neuropathy and metastasis-related pain.

---

Suggested Next Steps:

1. PSMA PET/CT:
   Confirm PSMA expression levels to determine RLT eligibility.

2. Multidisciplinary Evaluation:
   Involve oncology, nephrology, and pain management teams to refine the treatment plan.

3. Monitor Disease Progression:
   Regular imaging and PSA monitoring will guide treatment adaptation.

4. Patient-Centric Discussion:
   Discuss the risks, benefits, and likely outcomes of each approach, keeping quality of life as a central focus.

In summary, RLT with Lutetium-177 PSMA-617 is a strong next option if PSMA expression is confirmed. If RLT is not feasible, chemotherapy with careful dose adjustments or clinical trial participation may be the next best step.